Cancer-focused biotechnology company Kazia Therapeutics will present recent positive interim efficacy data on its lead program, paxalisib, at Biotech Showcase in San Francisco. Paxalisib (formerly known as GDC-0084) is a small molecule inhibitor of the PI3K pathway, which is b...